Novartis has secured European Commission approval for Itvisma, a one-time gene replacement therapy for a broad group of patients...
Read MoreAgomab Therapeutics is preparing to begin dosing patients in its phase 2b NOV-ERA study of ontunisertib for fibrostenosing Crohn’s...
Read MoreTeva Pharmaceutical Industries has submitted a New Drug Application to the U.S. Food and Drug Administration for ecopipam, an...
Read MoreAnocca has treated the first patients with its precision TCR T cell therapy, ANOC 001. NICE has recommended the...
Read MoreJohnson & Johnson’s nipocalimab met the primary endpoint in the phase 2 JASMINE study involving adults with moderate-to-severe systemic...
Read MoreResolution Therapeutics has welcomed four-year follow-up data from the University of Edinburgh’s MATCH trial into regenerative macrophage therapy for...
Read More